A Phase 3 interventional study of M923 and Humira in Chronic Plaque Psoriasis and Psoriasis, sponsored by Momenta Pharmaceuticals, Inc.. Completed at 90 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.
Sponsored by Momenta Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 3rd largest by enrollment, is one of 3 that started in 2015, is one of 26 in phase 3, and was the 32nd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 572 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
This study is registered under Momenta Pharmaceuticals, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Momenta Pharmaceuticals, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
76 studies in Psoriasis by Johnson & Johnson: 3 open now, 12 under way, 7 of them phase 3. Of 64 finished, 33 (52%) have results posted.
Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 15th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2015, is one of 36 in phase 3, and was the 46th registered.
Johnson & Johnson’s Psoriasis studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 76 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to receive M923
Biological: M923
Participants assigned to receive Humira
Biological: Humira
Participants assigned to receive M923 and Humira
Biological: M923 · Biological: Humira
Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
Also known as: Adalimumab
Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
Also known as: Adalimumab
Percentage of Participants Who Achieved a 75% Reduction in Psoriasis Area and Severity Index (PASI) (PASI 75) Scores at Week 16
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 75 are defined as having an improvement (reduction) of at least 75% in the Week 16 PASI score compared to the score at Baseline.
Time frame: Baseline; Week 16
Percentage of Participants With a Response of Clear or Almost Clear on the Static Physician Global Assessment (sPGA) at Week 16
The sPGA response rate was defined as the percentage of participants who had achieved a clear or almost clear response on the 6-point sPGA scale. The sPGA was the physician's determination of the participant's psoriasis lesions overall at a given time point. Overall lesions were categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis was assessed at a given time point on a 6-point scale on which 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe.
Time frame: Week 16
Number of Participants Achieving PASI 50 Response at Week 16
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 50 are defined as having an improvement (reduction) of at least 50% compared to Baseline.
Time frame: Baseline; Week 16
Number of Participants Achieving PASI 50 Response at Week 52 (Follow-Up Visit)
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 50 are defined as having an improvement (reduction) of at least 50% compared to Baseline.
Time frame: Baseline; Week 52
Number of Participants Achieving PASI 75 Response at Week 52 (Follow-Up Visit)
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 75 are defined as having an improvement (reduction) of at least 75% compared to Baseline.
Time frame: Baseline; Week 52
Number of Participants Achieving PASI 90 Response at Week 16
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 90 are defined as having an improvement (reduction) of at least 90% compared to Baseline.
Time frame: Baseline; Week 16
Number of Participants Achieving PASI 90 Response at Week 52 (Follow-Up Visit)
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 90 are defined as having an improvement (reduction) of at least 90% compared to Baseline.
Time frame: Baseline; Week 52
Absolute PASI Score at Baseline
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.
Time frame: Baseline
Absolute PASI Score at Week 16
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.
Time frame: Week 16
Absolute PASI Score at Week 52 (Follow-Up Visit)
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.
Time frame: Week 52
Percent Change From Baseline in PASI Score at Week 16
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Percent change from Baseline was calculated as: (post-Baseline value - Baseline value) / (Baseline value) \* 100.
Time frame: Baseline; Week 16
Percent Change From Baseline in PASI Score at Week 52 (Follow-Up Visit)
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Percent change from Baseline was calculated as: (post-Baseline value - Baseline value) / (Baseline value) \* 100.
Time frame: Baseline; Week 52
Health-Related Quality of Life During Treatment: Dermatology Life Quality Index (DLQI) Score at Baseline
The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.
Time frame: Baseline
Health-Related Quality of Life During Treatment: DLQI Score at Week 16
The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.
Time frame: Week 16
Health-Related Quality of Life During Treatment: DLQI Score at Week 48 (Completion/Termination Visit)
The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.
Time frame: Week 48
Health-Related Quality of Life During Treatment: EuroQoL 5-Dimension Health Status Questionnaire (EQ-5D-5L) at Baseline
The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine". Baseline was defined as the last scheduled observation prior to dosing, typically Day 1, predose.
Time frame: Baseline
Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 16
The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine".
Time frame: Week 16
Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 48 (Completion/Termination Visit)
The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine".
Time frame: Week 48
Number of Participants With Clinically Meaningful Changes in Vital Signs
Vital signs included body temperature, respiratory rate, pulse rate, systolic and diastolic blood pressure, and weight. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.
Time frame: Up to Week 52
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Baseline
Laboratory results included hematology \[Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes, Eosinophils absolute, and Eosinophils\], chemistry (Aspartate transaminase, Alanine transaminase, Gamma glutamyl transferase, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Potassium, Urea, Creatinine, Phosphate, Glucose, and Uric acid) and urinalysis \[Specific Gravity\] parameters. Laboratory results of a few hematology (Red Blood Cell Count and Monocytes absolute), chemistry (Alkaline Phosphatase, Total bilirubin, Sodium, Chloride, and Albumin), and urinalysis (pH) parameters were not assessed at Baseline and Week 16. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.
Time frame: Baseline
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Week 16
Laboratory results included hematology \[Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes, Eosinophils absolute, and Eosinophils\], chemistry (Aspartate transaminase, Alanine transaminase, Gamma glutamyl transferase, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Potassium, Urea, Creatinine, Phosphate, Glucose, and Uric acid) and urinalysis \[Specific Gravity\] parameters. Laboratory results of a few hematology (Red Blood Cell Count and Monocytes absolute), chemistry (Alkaline Phosphatase, Total bilirubin, Sodium, Chloride, and Albumin), and urinalysis (pH) parameters were not assessed at Baseline and Week 16. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.
Time frame: Week 16
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters at Week 48 (Completion/Termination Visit)
Laboratory results included hematology \[Red Blood Cell Count, Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes absolute, Monocytes, Eosinophils absolute, and Eosinophils\], chemistry (Aspartate transaminase, Alanine transaminase, Alkaline Phosphatase, Gamma glutamyl transferase, Total bilirubin, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Sodium, Potassium, Chloride, Urea, Creatinine, Albumin, Phosphate, Glucose, and Uric acid) and urinalysis \[pH and Specific Gravity\] parameters. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.
Time frame: Week 48
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Baseline
Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.
Time frame: Baseline
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 16
Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.
Time frame: Week 16
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 48 (Completion/Termination Visit)
Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.
Time frame: Week 48
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs are adverse events that occurred during or after study drug administration. For more details on adverse events please refer the safety section.
Time frame: Up to Week 52
Pharmacokinetics: Serum Concentrations by Treatment
Serum samples were collected at Baseline (Week 0, perdose), approximately 1 week (peak) after IP administration (Weeks 8 and 16), and 2 weeks after dose administration as a trough sample collected prior to the next dose administration (Weeks 17, 21, 25, 29, 37, 41).
Time frame: Baseline (Week 0), Week 8, 16, 17, 21, 25, 29, 37, and 41
Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA) at Baseline
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.
Time frame: Baseline (Week 0)
Immunogenicity: Number of Participants With ADA at Week 16
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.
Time frame: Week 16
Immunogenicity: Number of Participants With ADA at Week 25
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.
Time frame: Week 25
Immunogenicity: Number of Participants With ADA at Week 52 (Completion/Termination Visit)
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.
Time frame: Week 52
Immunogenicity: Number of Participants With ADA and nADA by Titer at Baseline
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.
Time frame: Baseline (Week 0)
Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 16
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.
Time frame: Week 16
Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 25
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.
Time frame: Week 25
Immunogenicity: Number of Participants With ADA and nADA by Titer at Week 52 (Completion/Termination Visit)
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.
Time frame: Week 52
Median Time to Seroconversion
Time to seroconversion (in days) was defined as the time to the observation of the first confirmed positive ADA response. Participants with confirmed positive ADA response at baseline (Week 0 predose) were excluded.
Time frame: Up to Week 52
A total of 572 participants were enrolled and randomized equally into M923 and European Union reference protein product (EU RPP) arms. One participant in each arm did not receive any treatment. The 263 participants completing EU RPP treatment in Part 1 were randomized to 1 of 2 treatment arms in Part 2 (Transition and Continuous).
| Milestone | Part 1 and Part 2: M923 | Part 1: EU RPP | Part 1: EU RPP; Part 2: Transition | Part 1: EU RPP; Part 2: Continous |
|---|---|---|---|---|
| Started | 286 | 286 | 0 | 0 |
| Completed | 271 | 263 | 0 | 0 |
| Not completed | 15 | 23 | 0 | 0 |
| Withdrew: Adverse event | 3 | 8 | 0 | 0 |
| Withdrew: Physician decision | 2 | 4 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 7 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 |
| Withdrew: Unspecified reason | 3 | 3 | 0 | 0 |
| Withdrew: Did not receive treatment | 1 | 1 | 0 | 0 |
| Milestone | Part 1 and Part 2: M923 | Part 1: EU RPP | Part 1: EU RPP; Part 2: Transition | Part 1: EU RPP; Part 2: Continous |
|---|---|---|---|---|
| Started | 271 | 0 | 132 | 131 |
| Completed | 242 | 0 | 117 | 119 |
| Not completed | 29 | 0 | 15 | 12 |
| Withdrew: Adverse event | 5 | 0 | 2 | 2 |
| Withdrew: Physician decision | 3 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 9 | 0 | 7 | 5 |
| Withdrew: Failure to achieve at least a pasi 50 | 8 | 0 | 3 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 1 |
| Withdrew: Unspecified reason | 2 | 0 | 1 | 1 |
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 75 are defined as having an improvement (reduction) of at least 75% in the Week 16 PASI score compared to the score at Baseline.
| percentage of participants | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Percentage of Participants Who Achieved a 75% Reduction in Psoriasis Area and Severity Index (PASI) (PASI 75) Scores at Week 16 | 80.1 (74.9 to 84.8) | 79.0 (73.6 to 83.7) |
The sPGA response rate was defined as the percentage of participants who had achieved a clear or almost clear response on the 6-point sPGA scale. The sPGA was the physician's determination of the participant's psoriasis lesions overall at a given time point. Overall lesions were categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis was assessed at a given time point on a 6-point scale on which 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe.
| percentage of participants | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Percentage of Participants With a Response of Clear or Almost Clear on the Static Physician Global Assessment (sPGA) at Week 16 | 68.9 (63.0 to 74.4) | 66.1 (60.1 to 71.7) |
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 50 are defined as having an improvement (reduction) of at least 50% compared to Baseline.
| Participants | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Number of Participants Achieving PASI 50 Response at Week 16 | 243 | 253 |
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 50 are defined as having an improvement (reduction) of at least 50% compared to Baseline.
| Participants | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| Number of Participants Achieving PASI 50 Response at Week 52 (Follow-Up Visit) | 228 | 111 | 113 |
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 75 are defined as having an improvement (reduction) of at least 75% compared to Baseline.
| Participants | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| Number of Participants Achieving PASI 75 Response at Week 52 (Follow-Up Visit) | 202 | 96 | 101 |
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 90 are defined as having an improvement (reduction) of at least 90% compared to Baseline.
| Participants | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Number of Participants Achieving PASI 90 Response at Week 16 | 165 | 147 |
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Participants achieving PASI 90 are defined as having an improvement (reduction) of at least 90% compared to Baseline.
| Participants | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| Number of Participants Achieving PASI 90 Response at Week 52 (Follow-Up Visit) | 159 | 71 | 77 |
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.
| units on a scale | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Absolute PASI Score at Baseline | 21.34 ± 9.268 | 20.29 ± 8.266 |
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.
| units on a scale | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Absolute PASI Score at Week 16 | 2.58 ± 4.092 | 2.50 ± 3.098 |
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score.
| units on a scale | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| Absolute PASI Score at Week 52 (Follow-Up Visit) | 2.76 ± 4.768 | 2.85 ± 4.913 | 2.67 ± 3.919 |
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Percent change from Baseline was calculated as: (post-Baseline value - Baseline value) / (Baseline value) \* 100.
| percent change | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Percent Change From Baseline in PASI Score at Week 16 | -86.21 ± 20.065 | -86.79 ± 15.756 |
The PASI combines assessments of the extent of body surface involvement in 4 anatomical regions (head, arms, trunk, and legs) and the severity of scaling, redness, and thickness in each region, yielding an overall score of 0 for no disease to 72 for the most severe disease. Each of the body areas was scored by itself, and then the 4 scores were combined into the final PASI score. Percent change from Baseline was calculated as: (post-Baseline value - Baseline value) / (Baseline value) \* 100.
| percent change | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| Percent Change From Baseline in PASI Score at Week 52 (Follow-Up Visit) | -86.43 ± 22.570 | -85.53 ± 21.771 | -85.64 ± 20.968 |
The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.
| units on a scale | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Health-Related Quality of Life During Treatment: Dermatology Life Quality Index (DLQI) Score at Baseline | 12.5 ± 7.13 | 10.5 ± 6.71 |
The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.
| units on a scale | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Health-Related Quality of Life During Treatment: DLQI Score at Week 16 | 2.4 ± 4.04 | 2.1 ± 3.50 |
The DLQI score was calculated by summing the individual scores of each question at a given time point, resulting in a maximum score of 30 and a minimum score of 0. The higher the score, the more quality of life is impaired. For the analysis of responses, the participant's results were assessed on a scoring scale on which 3 = very much or yes (applicable to question 7 only), 2 = a lot, 1 = a little, 0 = not at all or not relevant. Interpretation of DLQI scoring can be taken as 0 - 1 = no effect at all on participant's life, 2 - 5 = small effect on participant's life, 6 - 10 = moderate effect on participant's life, 11 - 20 = very large effect on participant's life, and 21 - 30 = extremely large effect on participant's life.
| units on a scale | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| Health-Related Quality of Life During Treatment: DLQI Score at Week 48 (Completion/Termination Visit) | 2.1 ± 3.77 | 1.6 ± 2.83 | 2.1 ± 3.97 |
The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine". Baseline was defined as the last scheduled observation prior to dosing, typically Day 1, predose.
| units on a scale | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Health-Related Quality of Life During Treatment: EuroQoL 5-Dimension Health Status Questionnaire (EQ-5D-5L) at Baseline | 71.3 ± 18.70 | 72.5 ± 20.27 |
The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine".
| units on a scale | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 16 | 83.7 ± 12.38 | 83.4 ± 13.92 |
The EQ-5D-5L health score was measured on a Visual Analog Scale (VAS) anchored by 0 = "worst health you can imagine" and 100 = "best health you can imagine".
| units on a scale | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| Health-Related Quality of Life During Treatment: EQ-5D-5L at Week 48 (Completion/Termination Visit) | 85.3 ± 13.83 | 83.9 ± 14.92 | 84.2 ± 12.98 |
Vital signs included body temperature, respiratory rate, pulse rate, systolic and diastolic blood pressure, and weight. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.
| Participants | Part 1: M923 | Part 1: EU RPP | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Changes in Vital Signs | 0 | 0 | 0 | 0 | 0 |
Laboratory results included hematology \[Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes, Eosinophils absolute, and Eosinophils\], chemistry (Aspartate transaminase, Alanine transaminase, Gamma glutamyl transferase, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Potassium, Urea, Creatinine, Phosphate, Glucose, and Uric acid) and urinalysis \[Specific Gravity\] parameters. Laboratory results of a few hematology (Red Blood Cell Count and Monocytes absolute), chemistry (Alkaline Phosphatase, Total bilirubin, Sodium, Chloride, and Albumin), and urinalysis (pH) parameters were not assessed at Baseline and Week 16. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.
| Participants | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Hemoglobin | 0 | 0 |
| Hematocrit | 0 | 0 |
| Platelet count | 0 | 0 |
| Mean cell volume | 0 | 0 |
| White blood cell count (total leucocytes) | 1 | 1 |
| Neutrophils absolute | 2 | 1 |
| Neutrophils | 1 | 0 |
| Lymphocytes absolute | 1 | 1 |
| Lymphocytes | 1 | 1 |
| Monocytes | 0 | 0 |
| Eosinophils absolute | 0 | 0 |
| Eosinophils | 0 | 0 |
| Aspartate transaminase | 0 | 0 |
| Alanine transaminase | 1 | 1 |
| Gamma glutamyl transferase | 1 | 4 |
| Creatine kinase | 2 | 0 |
| C-reactive protein | 6 | 2 |
| Cholesterol | 2 | 4 |
| Triglycerides | 3 | 2 |
| Total protein | 0 | 1 |
| Potassium | 1 | 0 |
| Urea | 1 | 0 |
| Creatinine | 0 | 0 |
| Phosphate | 0 | 0 |
| Glucose | 1 | 2 |
| Uric acid | 2 | 0 |
| Specific Gravity | 0 | 0 |
Laboratory results included hematology \[Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes, Eosinophils absolute, and Eosinophils\], chemistry (Aspartate transaminase, Alanine transaminase, Gamma glutamyl transferase, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Potassium, Urea, Creatinine, Phosphate, Glucose, and Uric acid) and urinalysis \[Specific Gravity\] parameters. Laboratory results of a few hematology (Red Blood Cell Count and Monocytes absolute), chemistry (Alkaline Phosphatase, Total bilirubin, Sodium, Chloride, and Albumin), and urinalysis (pH) parameters were not assessed at Baseline and Week 16. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.
| Participants | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Hemoglobin | 1 | 1 |
| Hematocrit | 1 | 1 |
| Platelet count | 0 | 0 |
| Mean cell volume | 0 | 1 |
| White blood cell count (total leucocytes) | 2 | 0 |
| Neutrophils absolute | 1 | 0 |
| Neutrophils | 0 | 0 |
| Lymphocytes absolute | 0 | 1 |
| Lymphocytes | 0 | 1 |
| Monocytes | 0 | 0 |
| Eosinophils absolute | 1 | 0 |
| Eosinophils | 1 | 0 |
| Aspartate transaminase | 2 | 0 |
| Alanine transaminase | 3 | 1 |
| Gamma glutamyl transferase | 3 | 2 |
| Creatine kinase | 2 | 0 |
| C-reactive protein | 1 | 0 |
| Cholesterol | 4 | 3 |
| Triglycerides | 5 | 3 |
| Total protein | 0 | 1 |
| Potassium | 1 | 0 |
| Urea | 0 | 0 |
| Creatinine | 0 | 0 |
| Phosphate | 0 | 0 |
| Glucose | 2 | 3 |
| Uric acid | 1 | 1 |
| Specific Gravity | 0 | 0 |
Laboratory results included hematology \[Red Blood Cell Count, Hemoglobin, Hematocrit, Platelet count, Mean cell volume, White blood cell count (total leucocytes), Neutrophils absolute, Neutrophils, Lymphocytes absolute, Lymphocytes, Monocytes absolute, Monocytes, Eosinophils absolute, and Eosinophils\], chemistry (Aspartate transaminase, Alanine transaminase, Alkaline Phosphatase, Gamma glutamyl transferase, Total bilirubin, Creatine kinase, C-reactive protein, Cholesterol, Triglycerides, Total protein, Sodium, Potassium, Chloride, Urea, Creatinine, Albumin, Phosphate, Glucose, and Uric acid) and urinalysis \[pH and Specific Gravity\] parameters. Clinically meaningful changes were classified as such by the Investigator and reported as adverse events.
| Participants | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| Red Blood Cell Count | 1 | 0 | 1 |
| Hemoglobin | 1 | 0 | 1 |
| Hematocrit | 1 | 0 | 1 |
| Platelet count | 1 | 0 | 0 |
| Mean cell volume | 0 | 0 | 1 |
| White blood cell count (total leucocytes) | 2 | 1 | 1 |
| Neutrophils absolute | 3 | 1 | 2 |
| Neutrophils | 3 | 0 | 0 |
| Lymphocytes absolute | 0 | 0 | 1 |
| Lymphocytes | 1 | 0 | 0 |
| Monocytes absolute | 0 | 0 | 0 |
| Monocytes | 1 | 0 | 0 |
| Eosinophils absolute | 0 | 0 | 0 |
| Eosinophils | 2 | 0 | 0 |
| Aspartate transaminase | 2 | 0 | 1 |
| Alanine transaminase | 5 | 0 | 3 |
| Alkaline Phosphatase | 0 | 0 | 0 |
| Gamma glutamyl transferase | 3 | 0 | 3 |
| Total bilirubin | 1 | 0 | 1 |
| Creatine kinase | 0 | 1 | 1 |
| C-reactive protein | 3 | 0 | 0 |
| Cholesterol | 7 | 3 | 2 |
| Triglycerides | 11 | 4 | 2 |
| Total protein | 0 | 0 | 0 |
| Sodium | 0 | 0 | 0 |
| Potassium | 0 | 0 | 0 |
| Chloride | 0 | 0 | 0 |
| Urea | 0 | 0 | 0 |
| Creatinine | 0 | 0 | 0 |
| Albumin | 0 | 0 | 0 |
| Phosphate | 0 | 0 | 0 |
| Glucose | 5 | 3 | 0 |
| Uric acid | 1 | 3 | 3 |
| pH | 1 | 1 | 0 |
| Specific Gravity | 0 | 0 | 0 |
Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.
| Participants | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Baseline | 0 | 0 |
Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.
| Participants | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 16 | 2 | 0 |
Clinically significant abnormalities were classified as such by the Investigator and reported as adverse events.
| Participants | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Electrocardiogram Parameters at Week 48 (Completion/Termination Visit) | 3 | 0 | 0 |
TEAEs are adverse events that occurred during or after study drug administration. For more details on adverse events please refer the safety section.
| Participants | Part 1: M923 | Part 1: EU RPP | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 169 | 194 | 199 | 99 | 103 |
Serum samples were collected at Baseline (Week 0, perdose), approximately 1 week (peak) after IP administration (Weeks 8 and 16), and 2 weeks after dose administration as a trough sample collected prior to the next dose administration (Weeks 17, 21, 25, 29, 37, 41).
| nanograms per milliter (ng/mL) | Part 1: M923 | Part 1: EU RPP | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|---|---|
| Baseline (Week 0)/Predose | 302 ± 16.5 | 301 ± 9.69 | — | — | — |
| Week 8/Peak | 9100 ± 5450 | 7640 ± 4370 | — | — | — |
| Week 16/Peak | 8580 ± 5700 | 6990 ± 5100 | — | — | — |
| Week 17/Trough | — | — | 6900 ± 5270 | 5840 ± 4840 | 5340 ± 4050 |
| Week 21/Trough | — | — | 6630 ± 4960 | 6260 ± 4960 | 5100 ± 4040 |
| Week 25/Trough | — | — | 6790 ± 5210 | 6320 ± 5260 | 4970 ± 3870 |
| Week 29/Trough | — | — | 5990 ± 4020 | 5330 ± 4000 | 4840 ± 3480 |
| Week 37/Trough | — | — | 6120 ± 4220 | 5250 ± 4190 | 4830 ± 3680 |
| Week 41/Trough | — | — | 5950 ± 4230 | 5480 ± 4140 | 4740 ± 3710 |
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.
| Participants | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| EU Humera | 15 | 11 |
| M923 | 1 | 2 |
| Overall Results | 16 | 13 |
| Neutralizing ADA | 4 | 2 |
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.
| Participants | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| EU Humera | 135 | 144 |
| M923 | 4 | 8 |
| Overall Results | 139 | 152 |
| Neutralizing ADA | 28 | 30 |
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.
| Participants | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| EU Humera | 144 | 80 | 92 |
| M923 | 12 | 5 | 5 |
| Overall result | 156 | 85 | 97 |
| Neutralizing ADA | 55 | 25 | 32 |
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose; if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. The same convention applied for the neutralizing assay results.
| Participants | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| EU Humera | 131 | 73 | 80 |
| M923 | 10 | 6 | 7 |
| Overall result | 141 | 79 | 87 |
| Neutralizing ADA | 40 | 28 | 23 |
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.
| Participants | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| No positive result | 266 | 271 |
| Predose positive result | 16 | 13 |
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.
| Participants | Part 1: M923 | Part 1: EU RPP |
|---|---|---|
| Titers ≤ 1:16 (postdose positive ADAs) | 16 | 26 |
| Titers ≤ 1:16 (postdose positive nADAs) | 2 | 2 |
| Titers > 1:16 to ≤ 1:128 (postdose positive ADAs) | 90 | 73 |
| Titers > 1:16 to ≤ 1:128 (postdose positive nADAs) | 17 | 6 |
| Titers >1:128 to ≤ 1:152 (postdose positive ADAs) | 27 | 40 |
| Titers >1:128 to ≤ 1:152 (postdose positive nADAs) | 3 | 11 |
| Titers >1:152 (postdose positive ADAs) | 6 | 13 |
| Titers >1:152 (postdose positive nADAs) | 6 | 11 |
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.
| Participants | Part 1 and Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| Titers ≤ 1:16 (postdose positive ADAs) | 24 | 19 | 21 |
| Titers ≤ 1:16 (postdose positive nADAs) | 6 | 2 | 4 |
| Titers > 1:16 to ≤ 1:128 (postdose positive ADAs) | 86 | 37 | 42 |
| Titers > 1:16 to ≤ 1:128 (postdose positive nADAs) | 17 | 4 | 7 |
| Titers >1:128 to ≤ 1:152 (postdose positive ADAs) | 28 | 14 | 22 |
| Titers >1:128 to ≤ 1:152 (postdose positive nADAs) | 16 | 6 | 10 |
| Titers >1:152 (postdose positive ADAs) | 18 | 15 | 12 |
| Titers >1:152 (postdose positive nADAs) | 16 | 13 | 11 |
The M923 confirmation assay was evaluated only if the EU Humira confirmation assay was negative. Overall Result: a participant was considered to be positive if a confirmed positive result was observed at any assay (including predose); if a participant had either a negative result in the screening assay or a positive result at screening followed by a negative result in all confirmation tiers, the overall result was negative. Overall Status: a participant was considered to have developed ADA or neutralizing ADAs if a confirmed positive result was observed at any time during the treatment period inclusive of the predose results; the designation of negative required either a negative screening assay or a negative confirmation result at each sampling time. In confirmed positive samples, an assay was used to determine the relative titer of the ADA; a subsequent neutralizing antibodies assay was used to determine the presence of neutralizing antibodies.
| Participants | Part 1 and Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| Titers ≤ 1:16 (postdose positive ADAs) | 26 | 11 | 17 |
| Titers ≤ 1:16 (postdose positive nADAs) | 0 | 2 | 3 |
| Titers > 1:16 to ≤ 1:128 (postdose positive ADAs) | 62 | 37 | 38 |
| Titers > 1:16 to ≤ 1:128 (postdose positive nADAs) | 13 | 6 | 5 |
| Titers >1:128 to ≤ 1:152 (postdose positive ADAs) | 23 | 12 | 15 |
| Titers >1:128 to ≤ 1:152 (postdose positive nADAs) | 9 | 6 | 2 |
| Titers >1:152 (postdose positive ADAs) | 13 | 7 | 10 |
| Titers >1:152 (postdose positive nADAs) | 11 | 6 | 7 |
Time to seroconversion (in days) was defined as the time to the observation of the first confirmed positive ADA response. Participants with confirmed positive ADA response at baseline (Week 0 predose) were excluded.
| days | Part 1 and Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|
| Median Time to Seroconversion | 113.0 (52 to 372) | 113.0 (51 to 375) | 112.0 (54 to 373) |
Collected over Up to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: M923 | 0/285 (0%) | 4/285 (1.4%) | 92/285 (32.3%) |
| Part 1: EU RPP | 0/285 (0%) | 7/285 (2.5%) | 104/285 (36.5%) |
| Part 2: M923 | 0/271 (0%) | 10/271 (3.7%) | 96/271 (35.4%) |
| Part 2: Transition EU RPP | 0/132 (0%) | 10/132 (7.6%) | 47/132 (35.6%) |
| Part 2: Continuous EU RPP | 0/131 (0%) | 8/131 (6.1%) | 63/131 (48.1%) |
| Event | Part 1: M923 | Part 1: EU RPP | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|---|---|
| CardiomyopathyCardiac disorders | 0/285 | 0/285 | 1/271 | 0/132 | 1/131 |
| Left ventricular failureCardiac disorders | 0/285 | 0/285 | 0/271 | 0/132 | 1/131 |
| Drug-induced liver injuryHepatobiliary disorders | 0/285 | 0/285 | 0/271 | 0/132 | 1/131 |
| HypersensitivityImmune system disorders | 0/285 | 0/285 | 0/271 | 0/132 | 1/131 |
| Hip fractureInjury, poisoning and procedural complications | 0/285 | 0/285 | 0/271 | 0/132 | 1/131 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/285 | 0/285 | 0/271 | 1/132 | 1/131 |
| AppendicitisInfections and infestations | 0/285 | 0/285 | 1/271 | 0/132 | 1/131 |
| Peritonsillar abscessInfections and infestations | 0/285 | 0/285 | 0/271 | 0/132 | 1/131 |
| Ejection fraction decreasedInvestigations | 0/285 | 0/285 | 0/271 | 0/132 | 1/131 |
| UreterolithiasisRenal and urinary disorders | 0/285 | 0/285 | 0/271 | 0/132 | 1/131 |
| Event | Part 1: M923 | Part 1: EU RPP | Part 2: M923 | Part 2: Transition EU RPP | Part 2: Continuous EU RPP |
|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 68/285 | 79/285 | 27/271 | 15/132 | 19/131 |
| PsoriasisSkin and subcutaneous tissue disorders | 8/285 | 8/285 | 28/271 | 14/132 | 21/131 |
| NasopharyngitisInfections and infestations | 19/285 | 17/285 | 40/271 | 16/132 | 20/131 |
| Upper respiratory tract infectionInfections and infestations | 9/285 | 6/285 | 15/271 | 6/132 | 11/131 |
| HeadacheNervous system disorders | 9/285 | 10/285 | 2/271 | 7/132 | 5/131 |
Intent-to-Treat (ITT) Analysis Set: all consenting participants randomized to study treatment
| Age, Continuous(years) | Part 1 and Part 2: M923 | Part 1 and Part 2: EU RPP | Total |
|---|---|---|---|
| Mean | 44.6 ± 12.4 | 45.5 ± 12.9 | 45.0 ± 12.6 |
| Sex: Female, Male(Participants) | Part 1 and Part 2: M923 | Part 1 and Part 2: EU RPP | Total |
|---|---|---|---|
| Female | 95 | 100 | 195 |
| Male | 191 | 186 | 377 |
| Race (NIH/OMB)(Participants) | Part 1 and Part 2: M923 | Part 1 and Part 2: EU RPP | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 281 | 282 | 563 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Psoriasis Area and Severity Index (PASI) Score(units on a scale) | Part 1 and Part 2: M923 | Part 1 and Part 2: EU RPP | Total |
|---|---|---|---|
| Mean | 21.24 ± 9.27 | 20.16 ± 8.16 | 20.70 ± 8.74 |
| Number of Participants with the Indicated Static Physician's Global Assessment (sPGA) Score(Participants) | Part 1 and Part 2: M923 | Part 1 and Part 2: EU RPP | Total |
|---|---|---|---|
| Moderate | 170 | 182 | 352 |
| Severe | 103 | 91 | 194 |
| Very Severe | 12 | 12 | 24 |
| Clear | 0 | 0 | 0 |
| Almost Clear | 0 | 0 | 0 |
| Mild | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Sep 2015, a primary completion of Apr 2017 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2018, 1 year 5 months after primary completion. A results delay was requested in Apr 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
Momenta Pharmaceuticals, Inc. →